CIBC Asset Management
UBX

CIBC Asset Management’s Unity Biotechnology UBX Stock Holding History

CIBC Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,634
Closed -$17.4K – 1208
2024
Q1 		$17.4K Hold
10,634
– – ﹤0.01% 1124
2023
Q4 		$20.5K Hold
10,634
– – ﹤0.01% 1090
2023
Q3 		$25.5K Hold
10,634
– – ﹤0.01% 1035
2023
Q2 		$27.1K Hold
10,634
– – ﹤0.01% 1084
2023
Q1 		$17.3K Buy
+10,634
New +$42.6K ﹤0.01% 1061

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC Asset Management's UBX Position: Q2 2024 in Review

CIBC Asset Management sold out of Unity Biotechnology (UBX) in Q2 2024, closing a stake of 10,634 shares — an estimated $17.4K sold.

CIBC Asset Management first reported a position in UBX in Q1 2023 and held it in 5 quarters. The position peaked at $27.1K in Q2 2023. 39 funds tracked by Wall St. Rank hold UBX as of Q2 2024.

  • CIBC Asset Management reported no remaining Unity Biotechnology position as of Q2 2024 after selling out during the quarter.
  • CIBC Asset Management sold 10,634 Unity Biotechnology shares in Q2 2024, an estimated $17.4K.
  • CIBC Asset Management first reported a position in Unity Biotechnology in Q1 2023 and held it in 5 quarters.
  • CIBC Asset Management's Unity Biotechnology position peaked at $27.1K in Q2 2023.
  • 39 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2024.

Based on CIBC Asset Management's 13F filing for Q2 2024, filed 1 Aug 2024.